What is MIRA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MIRA?

P/E (TTM) is n/a and 52-week range is $0.51 to $1.75 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MIRA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MIRA?

The company profile lists net income (TTM) near -$14M, EPS (TTM) near -$0.32 when available from the market-data feed. Figures are informational and may lag live markets.

Where is MIRA Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Miami, Florida, US, 42M shares outstanding, ISIN US60458C1045 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

MIRA Pharmaceuticals Inc

$MIRA

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company is headquartered in Miami, Florida. The company went IPO on 2023-08-03. The firm is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The firm's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. The company holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.

Employees

Website

mirapharmaceuticals.com/

IPO

2023-08-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US60458C1045

Headquarters

Miami, Florida, US

Shares outstanding

42M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

5.42%

Browse other companiesFree AI scores and summaries for more stocks